Browsing Tag
Regeneron Pharmaceuticals
31 posts
Is the gMG treatment race entering a lower-burden dosing phase?
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today!
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
Regeneron Pharmaceuticals (NASDAQ: REGN) bets on data scale as TriNetX deal opens access to 300 million patient records
Regeneron is pairing with TriNetX to expand its health data reach and AI drug discovery ambitions. Read what the deal could change next.
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.
Dupixent keeps winning trials—but can it survive the real battle with payers?
Explore how payer dynamics and pricing strategy may pose the biggest challenge for Dupixent’s growth, beyond clinical trials or biologic competitors.
Is the FDA’s hold on Intellia a warning sign for in vivo CRISPR delivery across biotech?
Intellia’s nex-z trials face FDA hold after liver safety event. Learn how its extended cash runway to mid-2027 could reshape biotech investor confidence.
Is Dupixent now the gold standard for asthma with nasal polyps? Inside Sanofi and Regeneron’s big study win
Dupixent outperforms Xolair in phase 4 respiratory trial for chronic rhinosinusitis with asthma. Find out what this means for Sanofi and Regeneron’s growth.